RESEARKA

The evidence base for colchicine's effects on inflammaging-related immune biomarkers is limited in this corpus. Only one source, Mathiesen 2025, directly addresses colchicine in a diabetes population, describing an investigator-initiated, randomized, double-blind, placebo-controlled phase 2b trial (REC1TE) evaluating low-dose colchicine (0.5 mg/day) in individuals with type 1 diabetes to reduce residual inflammatory risk. However, this study is described in terms of its design and rationale, with no primary endpoint results reported, leaving the effect direction on immune markers as unclear. Ramuth 2026 provides observational data from an older adult cohort but examines cardiometabolic index rather than colchicine, yielding a null overall effect direction.

Citation Support

• source_1 Mohammadnia 2025
• source_2 Li 2025
• source_3 Ammirati 2026
• source_4 Pascart 2026
• source_5 Broekhoven 2022